SSA
VOR icon

Schonfeld Strategic Advisors’s Vor Biopharma VOR Stock Holding History

Schonfeld Strategic Advisors’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-671
Closed -$9.63K – 2580
2025
Q1 		$9.63K Buy
+671
New +$16.1K ﹤0.01% 2120

Other funds holding VOR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Schonfeld Strategic Advisors's VOR Position: Q2 2025 in Review

Schonfeld Strategic Advisors sold out of Vor Biopharma (VOR) in Q2 2025, closing a stake of 671 shares — an estimated $9.63K sold.

Schonfeld Strategic Advisors first reported a position in VOR in Q1 2025 and held it in 1 quarter. The position peaked at $9.63K in Q1 2025. 35 funds tracked by Wall St. Rank hold VOR as of Q2 2025.

  • Schonfeld Strategic Advisors reported no remaining Vor Biopharma position as of Q2 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 671 Vor Biopharma shares in Q2 2025, an estimated $9.63K.
  • Schonfeld Strategic Advisors first reported a position in Vor Biopharma in Q1 2025 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's Vor Biopharma position peaked at $9.63K in Q1 2025.
  • 35 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.